Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction (EDUCATE-AMI)
Acute Myocardial Infarction, Percutaneous Coronary Intervention
About this trial
This is an interventional treatment trial for Acute Myocardial Infarction focused on measuring Acute myocardial infarction, Percutaneous coronary intervention, No-reflow phenomenon, Vasodilator agents
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of acute myocardial infarction
- Vessel TIMI flow < grade Ⅲ post-PCI
Exclusion Criteria:
- Heart failure of New York Heart Association (NYHA) class Ⅲ to class Ⅳ
- Sick sinus syndrome
- Atrioventricular block (grade Ⅱ and above)
- SBP ≤ 90mmHg or cardiogenic shock
- Heart Rate ≤60 bpm
- Pregnancy
- Renal or hepatic failure
Sites / Locations
- Zhongshan Hospital Fudan University
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
D
V
N
If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.